ClinicalTrials.gg
RecruitingNCT06599697Updated Aug 5, 2026

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

A Phase 2 interventional study of Intravenously administered pooled human immunoglobulin (IVIG) in Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy, sponsored by University of Alabama at Birmingham. Recruiting at 5 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by University of Alabama at Birmingham · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Muscular Diseases with a site in United States — 19 open to participants now, 27 under way, 5 of them phase 3. Muscular Diseases · United States.

Planned enrollment
55th of 66
12 · median 38
Started
2025
with 5 others
Phase 2
10 of 99
3 open now
Primary completion
2026-12
later than 3 of 25 live
Registered
87th of 99
by date

Among the 99 studies in Muscular Diseases with a site in United States, this one is the 55th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 3 of the 25 other live ones, and was the 87th registered.

Muscular Diseases

232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.

Browse Muscular Diseases studies →

Open to participants now

19 of the 99 studies in Muscular Diseases with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Muscular Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled, double blinded phase 2 exploratory clinical trial of intravenously administered pooled human immunoglobulin (IVIG) in anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune mediated necrotizing myopathy (IMNM). Planned enrollment is 12 individuals with active anti-HMGCR IMNM meeting inclusion and exclusion criteria. Assuming 20% drop-out, the investigators anticipate 10 participants will complete all study assessments. Enrolled participants will be randomized 1:1 to either IVIG 2g/kg or placebo (0.9% sodium chloride at equivalent volume) at weeks 0, 4, and 8. The primary efficacy and co-primary safety and tolerability endpoints will be assessed at week 12. After the randomized phase of the trial, all participants will be offered to continue on to an open-label extension phase in which participants will receive IVIG at weeks 12, 16, and 20. Participants will then return at week 24 for a final non-infusion visit to reassess safety, tolerability, and efficacy outcome.

03

Conditions studied

  • Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 16 years
  • Anti-HMGCR antibody positive
  • MMT-8 score \< 142 (range 0-160)
  • Serum CK > 5x
  • Anti-HMGCR IMNM disease duration \< 36 months at screening
  • No moderate or severe respiratory or swallowing dysfunction due to anti-HMGCR IMNM at screening
  • No history of dermatomyositis rash
  • Must reside in a state with a participating research site

Exclusion criteria

Exclusion Criteria:

  • Oral (GC) daily dose > 15mg at screening
  • Change in oral GC dose \< 2 weeks prior to screening
  • Prior IVIG treatment for anti-HMGCR IMNM

    ->1 oral conventional synthetic DMARD (e.g. methotrexate, mycophenolate mofetil, azathioprine) use at screening

  • Change in concomitant DMARD dose \< 4 weeks prior to screening
  • Rituximab \< 6 months prior to screening
  • Plasma exchange, cyclophosphamide, or biologic medication \< 3 months prior to screening
  • Use of statin medication at screening
  • History of anaphylactic reaction to IVIG
  • History of angina pectoris, myocardial infarction, , or stroke \< 12 months prior to screening
  • Females of who are pregnant, breastfeeding, or are unwilling to practice a highly effective method of during the study
  • Wells Criteria for DVT score of 2 or more at screening
  • Wells Criteria for PE score of 4 or more at screening
  • Weight >120kg
  • History of cancer (excluding non-melanomatous skin cancer) \< 5 years prior to screening
  • History of pulmonary embolism or deep venous thromboembolism \< 3 years prior to screening
  • History of hyperviscosity or hypercoagulable state
  • Currently receiving anti-coagulation therapy (vitamin K antagonists, non-vitamin K oral anticoagulants [e.g. dabigatran, rivaroxaban, apixaban], parenteral anticoagulants [e.g. fondaparinux]. Note that oral anti- agents are allowed (e.g. aspirin, clopidogrel, ticlopidine).
  • (GFR) \<60mL/min at the time of screening
  • Any medical condition which, in the investigator's judgment, makes participation in the clinical trial unadvisable or which would interfere with evaluation of the study treatment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Intravenously Administered Pooled Human Immunoglobulin (IVIG)

    Participants will receive intravenously administered pooled human immunoglobulin (IVIG) 2g/kg every 4 weeks for 24 weeks.

    Biological: Intravenously administered pooled human immunoglobulin (IVIG)

  • No intervention
    Placebo

    Participants will receive an infusion of 0.9% sodium chloride solution every 4 weeks for 16 weeks at equivalent volume to corresponding IVIG weight-based dose.

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage change in serum creatine kinase (CK)

    Primary Efficacy Outcome

    Time frame: Week 0 to 12

07

Study locations

3 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Sep 19, 2024
StartActual
Oct 27, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jun 30, 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06599697
Responsible party
James Andrews (Assistant Professor of Medicine, University of Alabama at Birmingham) — Principal investigator
First posted
Sep 19, 2024
Start date
Oct 27, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

James Andrews, MD
Contact
jaandrews@uabmc.edu
(205) 934-1564
Hannah E Howell, MS
Contact
heburns@uabmc.edu
205-996-6552
James Andrews, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion